Arxis Heads Into Debut Print With Defensive Options Skew

ARXS heads into its first post-IPO earnings release with options markets pricing in far more caution than the recent price strength would suggest.

The put/call ratio hit 1.77 on October 28, a 52-week high and well above its 20-day average of 1.28. That marks nearly a full standard deviation above recent norms, reflecting heavier demand for downside protection directly ahead of the print. The shift is sharp and recent: through early October, the PCR sat below 0.65, meaning the flip toward puts has been compressed into roughly three weeks. The stock itself has held up, closing at $54.13, up 8% over the past month and 4.6% on the week. Borrow conditions are relaxed, with availability at 375%, meaning there are more than three shares available to lend for every one currently borrowed, and cost to borrow has eased to 0.64%, down 14% on the week. Short interest, running near 4.9 million shares and flat on the week, does not tell a story of aggressive positioning against the company.

The bull-bear debate centres on whether Arxis can sustain the growth trajectory that drove the stock 28% higher after its Q2 print. Bulls point to first-quarter revenue of $459 million, up 21% year on year, organic growth of 21% in the second quarter, and net leverage of just 1.8x, which leaves room for further acquisitions. The five deals completed since the IPO, including Omnetics, are expected to contribute roughly $59 million in revenue this year and $114 million in 2027. Bears focus on the downside scenarios: if defence sales soften or OEM ramp activity disappoints, revenue CAGRs through 2028 could compress to as low as 7.5%, dragging EBITDA toward $770 million against the base case of $1.1 billion. RBC Capital upgraded ARXS to Outperform on October 2, raising its target from $50 to $60, the most significant recent analyst move. The consensus mean target of $63.70 implies about 18% upside from the current price, and the broader direction of analyst revisions has been upward across multiple firms since the IPO.

The ownership structure is unusual for a recently listed company. Arcline Investment Management holds approximately 79% of shares, with a 13G filing disclosing an 81.75% stake as of August. Capital Research Global Investors and Capital International Investors each filed fresh 13Gs in August at around 5.2% apiece, suggesting meaningful institutional interest in the float beyond the dominant holder. Most of the public-market institutional positions reported as of September 30 appear to be new builds, consistent with a stock that listed in 2026 and is still being discovered by allocators. On the insider side, the most recent open-market purchases date to April 17, when multiple executives and directors bought shares at $28, roughly half the current price. No open-market sales appear on the record.

Today's print is less a test of whether Arxis can grow and more a test of whether the organic growth rate holds, whether Omnetics integrates cleanly, and whether management's long-run EBITDA doubling thesis is translating into numbers that justify a PE above 42 and EV/EBITDA near 26 on a stock that has nearly doubled since IPO day.